BACKGROUND & AIMS: Two major mutations are defined within the hemochromatosis gene, HFE. Although the effects of the C282Y substitution have been well characterized, the clinical significance of the C282Y/H63D state remains unclear. This study assessed the phenotypic expression in C282Y/H63D subjects as compared with C282Y homozygotes. METHODS: Data were obtained from 91 C282Y/H63D probands, 158 C282Y/H63D subjects identified through family screening, and 483 C282Y homozygotes. Subjects underwent clinical evaluation, genotyping, biochemical assessment, and liver biopsy examination where clinically indicated. RESULTS: C282Y/H63D probands had significantly less clinical and biochemical expression than C282Y homozygotes. Biochemical expression was higher in C282Y/H63D probands than in C282Y/H63D subjects identified through family screening (P < .001). Of the C282Y/H63D subjects with serum ferritin levels greater than 1000 mug/L, all had known comorbid factors that could have contributed to the increased ferritin level. Of the 51 C282Y/H63D subjects who underwent liver biopsy examination, significantly increased iron stores were present in 9 subjects and hepatic fibrosis was present in 13. Twelve of the 13 had evidence of hepatic steatosis, excess alcohol consumption, or diabetes. The mobilizable iron level was significantly higher in C282Y homozygous males than in compound heterozygous males (P < .001). Genetic screening of C282Y/H63D first-degree relatives detected 5 C282Y homozygotes. CONCLUSIONS: C282Y/H63D subjects referred for assessment had a high prevalence of increased iron indices but did not develop progressive clinical disease without comorbid factors such as steatosis, diabetes, or excess alcohol consumption. When fibrosis was seen, 1 or more comorbid factors almost always were present. Thus, phlebotomy therapy is warranted and cascade screening of relatives should be performed because expressing C282Y homozygotes may be detected.
BACKGROUND & AIMS: Two major mutations are defined within the hemochromatosis gene, HFE. Although the effects of the C282Y substitution have been well characterized, the clinical significance of the C282Y/H63D state remains unclear. This study assessed the phenotypic expression in C282Y/H63D subjects as compared with C282Y homozygotes. METHODS: Data were obtained from 91 C282Y/H63D probands, 158 C282Y/H63D subjects identified through family screening, and 483 C282Y homozygotes. Subjects underwent clinical evaluation, genotyping, biochemical assessment, and liver biopsy examination where clinically indicated. RESULTS: C282Y/H63D probands had significantly less clinical and biochemical expression than C282Y homozygotes. Biochemical expression was higher in C282Y/H63D probands than in C282Y/H63D subjects identified through family screening (P < .001). Of the C282Y/H63D subjects with serum ferritin levels greater than 1000 mug/L, all had known comorbid factors that could have contributed to the increased ferritin level. Of the 51 C282Y/H63D subjects who underwent liver biopsy examination, significantly increased iron stores were present in 9 subjects and hepatic fibrosis was present in 13. Twelve of the 13 had evidence of hepatic steatosis, excess alcohol consumption, or diabetes. The mobilizable iron level was significantly higher in C282Y homozygous males than in compound heterozygous males (P < .001). Genetic screening of C282Y/H63D first-degree relatives detected 5 C282Y homozygotes. CONCLUSIONS: C282Y/H63D subjects referred for assessment had a high prevalence of increased iron indices but did not develop progressive clinical disease without comorbid factors such as steatosis, diabetes, or excess alcohol consumption. When fibrosis was seen, 1 or more comorbid factors almost always were present. Thus, phlebotomy therapy is warranted and cascade screening of relatives should be performed because expressing C282Y homozygotes may be detected.
Authors: Ruben Hernaez; Edwina Yeung; Jeanne M Clark; Kris V Kowdley; Frederick L Brancati; Wen Hong Linda Kao Journal: J Hepatol Date: 2011-02-24 Impact factor: 25.083
Authors: Oriana Marques; Ana Rosa; Luciana Leite; Paula Faustino; Alexandra Rêma; Berta Martins da Silva; Graça Porto; Carlos Lopes Journal: Cancer Microenviron Date: 2016-12-27
Authors: Raymond Cheng; James C Barton; Elizabeth D Morrison; Pradyumna D Phatak; Edward L Krawitt; Stuart C Gordon; Kris V Kowdley Journal: J Clin Gastroenterol Date: 2009-07 Impact factor: 3.062
Authors: Douglas A Corley; Ai Kubo; T R Levin; Gladys Block; Laurel Habel; Gregory J Rumore; Charles Quesenberry; Patricia Buffler Journal: Dig Dis Sci Date: 2008-05-10 Impact factor: 3.199
Authors: Eriza S Secondes; Daniel F Wallace; Gautam Rishi; Gordon D McLaren; Christine E McLaren; Wen-Pin Chen; Louise E Ramm; Lawrie W Powell; Grant A Ramm; James C Barton; V Nathan Subramaniam Journal: Blood Cells Mol Dis Date: 2020-07-01 Impact factor: 3.039
Authors: Lyle C Gurrin; Nadine A Bertalli; Gregory W Dalton; Nicholas J Osborne; Clare C Constantine; Christine E McLaren; Dallas R English; Dorota M Gertig; Martin B Delatycki; Amanda J Nicoll; Melissa C Southey; John L Hopper; Graham G Giles; Gregory J Anderson; John K Olynyk; Lawrie W Powell; Katrina J Allen Journal: Hepatology Date: 2009-07 Impact factor: 17.425